BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 21718430)

  • 1. Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma.
    Shelley MD; Cleves A; Wilt TJ; Mason MD
    BJU Int; 2011 Jul; 108(2):168-79. PubMed ID: 21718430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
    Shelley M; Cleves A; Wilt TJ; Mason M
    Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future perspectives in advanced bladder cancer: is there a new standard?
    von der Maase H
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
    von der Maase H; Hansen SW; Roberts JT; Dogliotti L; Oliver T; Moore MJ; Bodrogi I; Albers P; Knuth A; Lippert CM; Kerbrat P; Sanchez Rovira P; Wersall P; Cleall SP; Roychowdhury DF; Tomlin I; Visseren-Grul CM; Conte PF
    J Clin Oncol; 2000 Sep; 18(17):3068-77. PubMed ID: 11001674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
    Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
    Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.
    Roberts JT; von der Maase H; Sengeløv L; Conte PF; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M
    Ann Oncol; 2006 May; 17 Suppl 5():v118-22. PubMed ID: 16807438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
    von der Maase H; Sengelov L; Roberts JT; Ricci S; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M
    J Clin Oncol; 2005 Jul; 23(21):4602-8. PubMed ID: 16034041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine Plus Cisplatin Split
    Izumi K; Iwamoto H; Yaegashi H; Shigehara K; Nohara T; Kadono Y; Mizokami A
    In Vivo; 2019; 33(1):167-172. PubMed ID: 30587618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer.
    Niedersüss-Beke D; Puntus T; Kunit T; Grünberger B; Lamche M; Loidl W; Böhm R; Kraischits N; Kudlacek S; Schramek P; Meran JG
    Oncology; 2017; 93(1):36-42. PubMed ID: 28399521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma.
    Miyake M; Shimizu T; Nishimura N; Kiba K; Maesaka F; Oda Y; Tachibana A; Tomizawa M; Ohmori C; Matsumura Y; Ichikawa K; Mizobuchi S; Yoshikawa T; Hori S; Morizawa Y; Gotoh D; Nakai Y; Anai S; Torimoto K; Aoki K; Tanaka N; Fujimoto K;
    Clin Genitourin Cancer; 2022 Apr; 20(2):196.e1-196.e9. PubMed ID: 34916166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
    Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
    Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.
    Hussain SA; Stocken DD; Riley P; Palmer DH; Peake DR; Geh JI; Spooner D; James ND
    Br J Cancer; 2004 Aug; 91(5):844-9. PubMed ID: 15292922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
    Halim A; Abotouk N
    Asia Pac J Clin Oncol; 2013 Mar; 9(1):60-5. PubMed ID: 22897883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine in advanced bladder cancer.
    von der Maase H
    Semin Oncol; 2001 Apr; 28(2 Suppl 7):11-4. PubMed ID: 11372046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer.
    Vogelzang NJ; Stadler WM
    Urology; 1999 Feb; 53(2):243-50. PubMed ID: 9933034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
    García-Donas J; Font A; Pérez-Valderrama B; Virizuela JA; Climent MÁ; Hernando-Polo S; Arranz JÁ; Del Mar Llorente M; Lainez N; Villa-Guzmán JC; Mellado B; González Del Alba A; Castellano D; Gallardo E; Anido U; García Del Muro X; Domènech M; Puente J; Morales-Barrera R; Pérez-Gracia JL; Bellmunt J
    Lancet Oncol; 2017 May; 18(5):672-681a. PubMed ID: 28389316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
    Linardou H; Aravantinos G; Efstathiou E; Kalofonos C; Anagnostopoulos A; Deliveliotis C; Bafaloukos D; Athanasios Dimopoulos M; Bamias A;
    Urology; 2004 Sep; 64(3):479-84. PubMed ID: 15351574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.